Molecular markers in prostate cancer. Part Ⅰ： predicting lethality

作     者：Sachin Agrawal William D. Dunsmuir 

作者机构：Department of Urology St. Peters Hospital Chertsey UK. agrawalsachin@*** 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2009年第11卷第1期

页      面：14-21页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：genetics neoplasm metastasis prostate cancer 

摘      要：Assessing the lethality of ‘early,’ potentially organ-confined prostate cancer （PCa） is one of the central controversies in modem-day urological clinical practice. Such cases are often considered for radical ‘curative’ treatment, although active surveillance may be equally appropriate for many men. Moreover, the balance between judicious intervention and overtreatment can be difficult to judge. The patient＇s age, comorbidities, family history and philosophy of self-health care can be weighed against clinical features such as the palpability of disease, the number and percentage of biopsy cores involved with the disease, histological grade, presenting prostate-specific antigen （PSA） and possible previous PSA kinetics. For many years, scientists and physicians have sought additional molecular factors that may be predictive for disease stage, progression and lethality. Usually, claims for a ‘new’ unique marker fall short of true clinical value. More often than not, such molecular markers are useful only in multivariate models. This review summarizes relevant molecular markers and models reported up to and including 2008.